secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001326732-24-000041
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M
----------------------------------------------------------------

- Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.
- Revenue $17.0M, down from $45.5M; primarily non-cash royalty and licensing; no J&J milestone.
- Cash $585M as of June 30, down from $697M at Dec 31; FY2024 cash guidance $475-525M.
- Regained exclusive worldwide rights to plamotamab (CD20 x CD3), a Phase 2-ready bispecific T-cell engager.
- Vudalimab (PD-1 x CTLA-4) data update and advancement decision for mCRPC expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/0001326732-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/xncr-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer